Kay Olmstead (CEO)
Meet the CEO
Kay Olmstead is a co-founder and CEO of Nano PharmaSolutions. Dr. Olmstead has over 31 years of experience in pharmaceutical industry in both API (drug substance) and finished dosage form development.
Prior to founding Nano PharmaSolutions, Dr. Olmstead served numerous small to medium pharmaceutical companies in worldwide as a CMC subject matter expert, especially in poorly soluble drug development. During past 20 years, Dr. Olmstead played a lead role in the development and the FDA approval of five commercial drugs for San Diego based companies, including Santarus, Inc. (NASDAQ: SNTR | acquired by Salix in 2013 for $2.6 billion) and Intercept Pharmaceutical (NASDAQ: ICPT).
Dr. Olmstead has published more than 12 manuscripts and has 11 issued patents and 3 pending patent applications. Dr.Olmstead received Ph.D. degree in Organic Chemistry at Johns Hopkins University followed by a NIH post-doctoral fellowship at Stanford University. She currently serves on as the Global Pharma Key Opinion Leader for Korean Health Industry Development Institute (KHIDI).
S.K. Koh (CTO)
Meet the CTO
Patricia Lady (CFO)
Meet the CFO
Patricia has over thirty year of experience in finance including start-ups as well as publicly traded companies. In her current role as CFO at Nano PharmaSolutions, she is a member of the leadership team developing and executing on financing strategy and responsible for developing administrative operational infrastructure supporting the dynamic growth of the company.
Prior to joining Nano PharmaSolutions, Patricia spent a decade at Pfenex Inc.. (PFNX), beginning with the spin out of the novel protein production platform from the Dow Chemical Company into a stand-alone biotechnology company. She was instrumental in developing and executing on Pfenex’s financial strategy that included an IPO and provided the capital needed to obtain FDA approval on its lead candidate and eventual final exit through acquisition.
Prior to Pfenex Inc, Patricia led finance and corporate development teams in the life science and technology industries of various start-ups and publicly traded companies.
Patricia received her MBA from the University of California, Los Angeles. She holds an active CPA license in the State of California.
Dr. Ingrid Niesman
Director of SDSU EMF – Particle Morphology
Debra Gessner, M.Sc.
Regulatory Affairs, Biosketch
Dr. Micheal Niesman
CSO of MingSight Biology & Pharmacology
Director of EMF Particle Morphology
Early in her career Dr. Ingrid Niesman performed research for various departments at UC San Diego. In 2014 she joined The Scripps Research Institute (TSRI) as a Postdoctoral Fellow. Dr. Ingrid Niesman is currently Director of San Diego State University’s (SDSU) Electron Microscopy Facility, which is affiliated with the Department of Biology. She has written articles for peer-reviewed journals and is considered an expert in particle analysis using scanning electron microscopy (SEM) and electron dispersive spectroscopy (EDS) as well as two-dimensional and three-dimensional cryo electron microscopy (cryoEM). Her extensive background in cell biology and particle analysis makes her a key member of Nano PharmaSolutions (NPS) Scientific Advisory Board (SAB).
Regulatory Affiars, Biosketch
Debra has over 30 years of hands—on submissions and senior management experience in Regulatory Affairs and compliance, including building and heading regulatory, QA and publishing teams, project team leadership, corporate partner management and due diligence activities. Regulatory experience encompasses Pre—IND thru submission, approval and launch of 5 marketed products. Directly responsible for the coordination, planning, review and submission of over 40 U.S. INDs, with CTA experience for Canada, Mexico, Australia, Hong Kong and EU member states. Product areas of expertise include viral and non-viral gene therapeutics, cell therapies, vaccine development and small and large molecule drugs. Proficient in expedited regulatory pathways including Breakthrough Product designations, Fast Track designations, and Orphan drug development. Familiar with 505(b)(2) products, drug-biologic combination products.
CSO of MingSight Biology & Pharmacology
GM of Daylight Solutions Laser Physics
Dr. Michael Niesman earned his Ph.D. in cell biology at University of Illinois and a Postdoctoral Fellowship at Louisiana State University. In the mid-1990s he was Assistant Professor of Ophthalmology, Pharmacology and Toxicology at University of Arkansas for Medical Scientist. He was Head of Ocular Pharmacology at Warner Lambert, Inc. He joined Pfizer and in time became Head of Ophthalmology Research. He is now Chief Scientific Officer at MingSight Pharmaceuticals. He contributed publications in peer-reviewed journals, is lead author on two patents and a contributor to a third patent. Dr. Niesman is a crucial member of Nano PharmaSolutions (NPS) Scientific Advisory Board because of his expertise in ocular pharmacology, ocular drug delivery and ocular drug development, a dosage form to which NPS intends devote a significant amount of its resources.